Litcius/Paper detail

SUMOylation as a Therapeutic Target for Myocardial Infarction

Wei Zhao, Xiuying Zhang, Jianhui Rong

2021Frontiers in Cardiovascular Medicine33 citationsDOIOpen Access PDF

Abstract

Myocardial infarction is a prevalent and life-threatening cardiovascular disease. The main goal of existing interventional therapies is to restore coronary reperfusion while few are designed to ameliorate the pathology of heart diseases via targeting the post-translational modifications of those critical proteins. Small ubiquitin-like modifier (SUMO) proteins are recently discovered to form a new type of protein post-translational modifications (PTM), known as SUMOylation. SUMOylation and deSUMOylation are dynamically balanced in the maintenance of various biological processes including cell division, DNA repair, epigenetic transcriptional regulation, and cellular metabolism. Importantly, SUMOylation plays a critical role in the regulation of cardiac functions and the pathology of cardiovascular diseases, especially in heart failure and myocardial infarction. This review summarizes the current understanding on the effects of SUMOylation and SUMOylated proteins in the pathophysiology of myocardial infarction and identifies the potential treatments against myocardial injury via targeting SUMO. Ultimately, this review recommends SUMOylation as a key therapeutic target for treating cardiovascular diseases.

Topics & Concepts

SUMO proteinMyocardial infarctionMedicineEpigeneticsHeart failureDiseaseBioinformaticsBiologyUbiquitinCardiologyInternal medicineGeneticsGeneUbiquitin and proteasome pathwaysATP Synthase and ATPases ResearchAutophagy in Disease and Therapy
SUMOylation as a Therapeutic Target for Myocardial Infarction | Litcius